Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's in...
Viveve, Inc., the wholly owned subsidiary of Vi...
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on th...
Sinovac Biotech Ltd. is a China-based biopharma...
Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sell...
Otsuka Holdings Co Ltd is a pharmaceutical comp...
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...
Immuron Ltd is a publicly listed Australian bio...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...
Join the National Investor Network and get the latest information with your interests in mind.